Eldelumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Eldelumab?
Monoclonal antibody
Source Human
Target interferon gamma-induced protein
Clinical data
Identifiers
946414-98-8
None
Chemical data
Formula C6502H10024N1736O2026S48
146.5 kDa

Eldelumab is a monoclonal antibody designed for the treatment of Crohn's disease and ulcerative colitis.[1]

This drug was developed by Bristol-Myers Squibb.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.